Diabetes technology company Tandem Diabetes Care (NASDAQ: TNDM) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.8% year on year to $254.6 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $1.08 billion at the midpoint. Its non-GAAP loss of $0.31 per share was in line with analysts’ consensus estimates.

Is now the time to buy TNDM? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Tandem Diabetes met Wall Street’s revenue and profit expectations in Q2, but the market responded negatively, likely reflecting investor caution around the pace of U.S. pump shipments and the near-term impact of the company’s business model transition. Management highlighted stronger pump shipment growth internationally and early traction from its new pharmacy channel in the U.S. CEO John Sheridan emphasized that the company’s ability to drive operational efficiencies and expand access to its technology contributed to improved margins and a more favorable product mix.

Looking ahead, Tandem Diabetes’ guidance is underpinned by expectations of continued pharmacy channel adoption, progress with new product launches—including the imminent rollout of Mobi tubeless—and expanding coverage in both U.S. and international markets. Management is focused on achieving a higher share of pharmacy-based recurring revenue while scaling new technologies and overcoming supply chain constraints. CFO Leigh Vosseller cautioned that the ramp-up of new pharmacy and infusion set offerings may create temporary margin variability, but expressed confidence that margin expansion will resume as adoption builds.

Key Insights from Management’s Remarks

Management attributed the quarter’s results to early success in the pharmacy channel, international growth, and margin improvements driven by cost discipline and product mix shifts.

• Pharmacy channel momentum: The launch of the pay-as-you-go (PAYGO) reimbursement model in the pharmacy channel drove 10% of U.S. sales in its first full quarter, signaling strong early adoption and improved affordability for new pump users.
• International direct expansion: Tandem’s move to direct sales in markets like the UK, Switzerland, and Austria accelerated international pump adoption, with international shipments up 19% year-over-year and direct channel revenue more than doubling versus last year.
• Product mix shift toward Mobi: The Mobi pump, Tandem’s compact device, now accounts for over half of new customer shipments, reflecting customer preference for smaller, flexible devices and supporting higher average selling prices.
• Gross margin recovery: Gross margin improved by 5 percentage points year-over-year, driven by pharmacy pricing, increasing Mobi scale, and operational efficiencies, despite ongoing supply constraints for infusion sets.
• Infusion set supply constraints: Management noted that supply challenges from a key infusion set supplier impacted both U.S. and international sales, but expects improvement through the second half of the year as new product launches like AutoSoft Plus help offset shortages.

Drivers of Future Performance

Management’s outlook centers on expanding pharmacy adoption, successful product launches, and ongoing international growth, while managing near-term supply chain and margin volatility.

• Pharmacy adoption scaling: Management expects an increasing share of U.S. pump shipments and recurring supply revenue to move through the pharmacy channel, benefiting from approximately 45% formulary coverage and a focus on operational efficiencies. However, near-term revenue optics may be pressured as pump adoption temporarily outpaces supply conversions.
• New product launches: The upcoming launch of Mobi tubeless, subject to FDA clearance, is anticipated to be a significant growth driver, providing a differentiated offering in the high-growth tubeless insulin pump segment. Management believes this will be an inflection point for both revenue and margin in 2027.
• Managing supply chain headwinds: While infusion set shortages are expected to lessen, management remains cautious about timing and potential short-term impacts on sales and margins, particularly in international markets. The introduction of new infusion set technologies aims to mitigate these risks over time.

Catalysts in Upcoming Quarters

In the coming quarters, our team will focus on (1) the pace of pharmacy channel adoption and its impact on recurring revenue, (2) the FDA clearance and market introduction of Mobi tubeless and related infusion set technologies, and (3) stabilization of supply chain dynamics as new products come online. Progress on type 2 diabetes segment penetration and international direct market launches will also be important markers for sustained growth.

Tandem Diabetes currently trades at $18.04, down from $18.79 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

High Quality Stocks for All Market Conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.